Legend Biotech Corporation Announces Proposed Public Offering
The company expects about $226 million in gross proceeds before fees and granted underwriters a 30-day option for 1,155,000 more ADSs.
6 Articles
6 Articles
Legend Biotech shares slide post-pricing of $226M public offering at
Legend Biotech (LEGN) has announced the pricing of an underwritten public offering of 7.7M American Depositary Shares ((ADSs)) at a public offering price of $29.35 per ADS. Each ADS represents two of the company's ordinary shares.
The Manila Times
stocktitan.netLegend Biotech Corporation Announces Pricing of Public Offering
BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) ('Legend Biotech” or the 'Company”), a global leader in cell therapy, today...
Legend Biotech Corporation Announces Pricing of Public Offering - Legend Biotech (NASDAQ:LEGN)
BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares ("ADSs"), each representing two ordinary shares of the Company, at a public offering price of $29.35 per ADS. In addition, Legend Biotech has granted the underwriters a 30-day option…
Hastings Tribune
Globe NewswireLegend Biotech Corporation Announces Proposed Public Offering
BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced that it has commenced an underwritten public offering of $225 million of American Depositary…
Coverage Details
Bias Distribution
- 60% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
